Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoclonal antibodies | 5849 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sugemalimab is a fully human immunoglobulin G4 monoclonal antibody. It specifically binds to programmed cell death ligand 1 (PD-L1), thus blocking its ligation with PD-1. PD-L1, when expressed on tumour cells and tumour-infiltrating immune cells, can contribute to the inhibition of an anti tumour immune response. Binding of PD-L1 to the PD-1 and CD80 (B7.1) receptors found on T-cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses without inducing antibody dependent cell-mediated cytotoxicity (ADCC).
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 24, 2024 | EMA | Cstone Pharmaceuticals Ireland Limited |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FF11 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Programmed cell death 1 ligand 1 | CD molecules | ANTIBODY BINDING | Kd | 8.86 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2256084-03-2 | SECONDARY_CAS_RN |
| CHEMBL4594535 | ChEMBL_ID |
| C000723018 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB16641 | DRUGBANK_ID |
| C5418251 | UMLSCUI |
| CHEBI:758009 | CHEBI |
| 11330 | INN_ID |
| 13444038 | PUBCHEM_CID |
| 12342 | IUPHAR_LIGAND_ID |
| 90IQR2I6TR | UNII |
| D12750 | KEGG_DRUG |
| 020273 | NDDF |
None